Clinical Audit of Anticoagulant Therapy with Pregnancy in Al-Emarati Hospital

Simple item page
dc.contributor.authorMustafa Abu Jayyab
dc.contributor.authorMosheer Al-Dhdouh
dc.contributor.authorKhamis Elessi
dc.date.accessioned2022-06-22T10:40:34Z
dc.date.available2022-06-22T10:40:34Z
dc.date.issued2022-05-11
dc.description.abstractBackground: Thromboembolic disorders can be considered a fatal problem in pregnancy. Anticoagulant therapy plays an important role in both treatment and prevention. Warfarin is the best drug to use but carries the risk of bleeding in mothers and fetuses, especially in the late pregnancy and delivery. Moreover, the risks of embryopathy from warfarin in early pregnancy cannot be excluded. Parenteral heparin has the advantage of the inability to cross the placental barrier but still can be a cause of bleeding problems in pregnancy, and its long-term use still carries the problems of maternal bone demineralization (Bates, Greer et al. 2012).
dc.identifier.urihttps://hdl.handle.net/20.500.12213/6578
dc.language.isoen
dc.publisherAl-Quds University, Deanship of Scientific Research
dc.titleClinical Audit of Anticoagulant Therapy with Pregnancy in Al-Emarati Hospital
dc.typeArticle
dspace.entity.type
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Clinical Audit of Anticoagulant Therapy with Pregnancy in Al-Emarati Hospital.pdf
Size:
222.17 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.61 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medicine